Results for tag: "Cholesteryl Ester Transfer Protein"

The Cholesteryl Ester Transfer Protein (CETP) market is a segment of the cardiovascular drugs market. CETP inhibitors are drugs that are used to reduce the risk of cardiovascular disease by increasing the levels of high-density lipoprotein (HDL) cholesterol in the blood. CETP inhibitors work by blocking the action of CETP, an enzyme that transfers cholesterol from HDL to low-density lipoprotein (LDL). This helps to reduce the amount of LDL cholesterol in the blood, which is associated with an increased risk of cardiovascular disease. CETP inhibitors are a relatively new class of drugs, and the market is still in its early stages. However, the potential of CETP inhibitors to reduce the risk of cardiovascular disease has led to increased interest in the market. Several companies are developing CETP inhibitors, including Merck, Pfizer, and Eli Lilly. Additionally, several biotechnology companies are researching CETP inhibitors, such as Esperion Therapeutics, Amgen, and Regeneron Pharmaceuticals. Show Less Read more